| The Food and Drug Administration's approval Friday of a first-of-its-kind gene-editing therapy offers hope to patients with sickle cell disease — a rare, but debilitating, genetic disorder that disproportionately affects Black people. The FDA approved the treatment, which requires a lengthy hospitalization and destroys patients' fertility, for those with the most severe cases. Read the latest | 
